Establishment of the national pregnancy registry for atypical antipsychotics

Journal of Clinical Psychiatry

Volumn 76, Issue 7, 2015, Pages 986-989

  Cohen, Lee S ^a   Viguera, Adele C ^a,b   McInerney, Kathryn A ^a,c   Kwiatkowski, Molly A ^a   Murphy, Shannon K ^a   Lemon, Elizabeth L ^a   Hernández Díaz, Sonia ^c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; NEUROLEPTIC AGENT;

ADULT; ARTICLE; CONGENITAL MALFORMATION; CONTROLLED STUDY; DRUG SAFETY; FEMALE; GESTATION PERIOD; HUMAN; INFORMATION PROCESSING; MAJOR CLINICAL STUDY; NATIONAL PREGNANCY REGISTRY FOR ATYPICAL ANTIPSYCHOTICS; PREGNANCY; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSYCHOLOGICAL WELL BEING; PUERPERIUM; REGISTRATION; RISK ASSESSMENT; TELEPHONE INTERVIEW; ABNORMALITIES, DRUG-INDUCED; ADOLESCENT; CLINICAL TRIAL; MIDDLE AGED; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; REGISTER; STATISTICS AND NUMERICAL DATA; UNITED STATES; YOUNG ADULT;

ABNORMALITIES, DRUG-INDUCED; ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; FEMALE; HUMANS; MIDDLE AGED; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; REGISTRIES; UNITED STATES; YOUNG ADULT;

EID: 84938151465     PISSN: 01606689     EISSN: 15552101     Source Type: Journal    
DOI: 10.4088/JCP.14br09418     Document Type: Article

References (27)

1. Holmes LB, Wyszynski DF. North American Antiepileptic Drug Pregnancy Registry. Epilepsia. 2004; 45(11):1465. doi:10.1111/j.0013-958.204451102. x PubMed
2. Tomson T, Battino D, Craig J, et al; ILAE Commission on Therapeutic Strategies. Pregnancy registries: differences, similarities, and possible harmonization. Epilepsia. 2010; 51(5): 909-915. doi:10.1111/j.528-167.201.025.x PubMed
3. US Food and Drug Administration. Pregnancy registries. http://www.fda.gov/ScienceResearch/SpecialTopics/WomensHealthResearch/ucm251314.htm. Updated July 22, 2011. Accessed January 22, 2015.
4. Cole JA, Modell JG, Haight BR, et al. Bupropion in pregnancy and the prevalence of congenital malformations. Pharmacoepidemiol Drug Saf. 2007;16(5):474-484.doi:10.102/pds.1296PubMed
5. Goldstein DJ, Corbin LA, Sundell KL. Effects of first-trimester fluoxetine exposure on the newborn. Obstet Gynecol. 1997;89(5 Pt 1):713-718. doi:10.016/S029-784(97)70-7 PubMed
6. Schou M, Goldfield MD, Weinstein MR, et al. Lithium and pregnancy, 1: report from the Register of Lithium Babies. BMJ. 1973; 2 (5859):135-136. doi:10.136/bmj2.859.135 PubMed
7. Kulkarni J, McCauley-Elsom K, Marston N, et al. Preliminary findings from the National Register of Antipsychotic Medication in Pregnancy. Aust N Z J Psychiatry. 2008;42(1):38-44. doi:10.18/0486070132723 PubMed
8. McCauley-Elsom K, Gurvich C, Elsom SJ, et al. Antipsychotics in pregnancy. J Psychiatr Ment Health Nurs. 2010;17(2):97-104. doi:10.1111/j.1365-285.209.0481.x PubMed
9. Alexander GC, Gallagher SA, Mascola A, et al. Increasing off-label use of antipsychotic medications in the United States, 1995-2008. Pharmacoepidemiol Drug Saf. 2011;20(2): 177-184. doi:10.102/pds.2082PubMed
10. Abel KM. Fetal antipsychotic exposure in a changing landscape: seeing the future. Br J Psychiatry. 2013;202(5):321-323. PubMed
11. Toh S, Li Q, Cheetham TC, et al. Prevalence and trends in the use of antipsychotic medications during pregnancy in the US, 2001-2007: a population-based study of 585, 615 deliveries. Arch Women Ment Health. 2013;16(2):149-157. doi:10.10/s077-01330-6
12. Ernst CL, Goldberg JF. The reproductive safety profile of mood stabilizers, atypical antipsychotics, and broad-spectrum psychotropics. J Clin Psychiatry. 2002;63(suppl 4):42-55. PubMed
13. Gentile S. Clinical utilization of atypical antipsychotics in pregnancy and lactation. Ann Pharmacother. 2004;38(7-8):1265-1271. doi:10.1345/aph.1D485 PubMed
14. McKenna K, Koren G, Tetelbaum M, et al. Pregnancy outcome of women using atypical antipsychotic drugs: a prospective comparative study. J Clin Psychiatry. 2005;66(4):444-449, quiz 546. doi:10.408/JCP.v6n406 PubMed
15. Yaeger D, Smith HG, Altshuler LL. Atypical antipsychotics in the treatment of schizophrenia during pregnancy and the postpartum. Am J Psychiatry. 2006;163(12):2064-2070. doi:10.176/ajp.20.1631.2064 PubMed
16. Einarson A, Boskovic R. Use and safety of antipsychotic drugs during pregnancy. J Psychiatr Pract. 2009;15(3):183-192. doi:10.197/01pra.00351878.45260.94 PubMed
17. Sadowski A, Todorow M, Yazdani Brojeni P, et al. Pregnancy outcomes following maternal exposure to second-generation antipsychotics given with other psychotropic drugs: a cohort study. BMJ Open. 2013;3(7). PubMed
18. Habermann F, Fritzsche J, Fuhlbrück F, et al. Atypical antipsychotic drugs and pregnancy outcome: a prospective, cohort study. J Clin Psychopharmacol. 2013;33(4):453-462. doi:10.1097/JCP.0b0e318295fe12 PubMed
19. Goldstein DJ, Corbin LA, Fung MC. Olanzapine-exposed pregnancies and lactation: early experience. J Clin Psychopharmacol. 2000;20(4):399-403. doi:10.197/00004714-200008-00002 PubMed
20. Reis M, Källén B. Maternal use of antipsychotics in early pregnancy and delivery outcome. J Clin Psychopharmacol. 2008;28(3):279-288. doi:10.1097/JCP.b01e38172b8d5PubMed
21. Newham JJ, Thomas SH, MacRitchie K, et al. Birth weight of infants after maternal exposure to typical and atypical antipsychotics: prospective comparison study. Br J Psychiatry. 2008;192(5):333-337. doi:10.1192/bjpbp107.0541 PubMed
22. Bodén R, Lundgren M, Brandt L, et al. Antipsychotics during pregnancy: relation to fetal and maternal metabolic effects. Arch Gen Psychiatry. 2012;69(7):715-721. doi:10.01/archgenpsychiatry.20.1870 PubMed
23. Johnson KC, LaPrairie JL, Brennan PA, et al. Prenatal antipsychotic exposure and neuromotor performance during infancy. Arch Gen Psychiatry. 2012;69(8):787-794. doi:10.01/archgenpsychiatry.012.160 PubMed
24. Peng M, Gao K, Ding Y, et al. Effects of prenatal exposure to atypical antipsychotics on postnatal development and growth of infants: a case-controlled, prospective study. Psychopharmacology (Berl). 2013;228(4):577-584. doi:10.107/s02131-3060-6 PubMed
25. Holmes LB, Wyszynski DF, Lieberman E. The AED (antiepileptic drug) Pregnancy Registry: a 6-year experience. Arch Neurol. 2004; 61(5): 673-678. doi:10.101/archneur61.5.673 PubMed
26. Holmes LB. Need for inclusion and exclusion criteria for the structural abnormalities recorded in children born from exposed pregnancies. Teratology. 1999;59(1):1-2. doi:10.102/(SCI)1096-926(1901)5930.CO;2-L PubMed
27. Källén B. The problem of confounding in studies of the effect of maternal drug use on pregnancy outcome. Obstet Gynecol Int. 2012;2012:148616. doi:10.15/2012/48616PubMed